<DOC>
	<DOCNO>NCT00060567</DOCNO>
	<brief_summary>E7070 irinotecan administer patient GI tract , pancreatic lung tumor Days 1 8 21-day cycle , Days 1 15 28-day cycle accord one two E7070 dose escalation scheme .</brief_summary>
	<brief_title>Dose-Finding Study E7070 Combination With Irinotecan</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm refractory small cell lung carcinoma relapse pancreatic cancer . 2 . Patients receive two previous regimen chemotherapy ( prior epidermal growth factor direct therapy antiangiogenic therapy , capecitabine constitute previous regimen ) , 3 . Patients must age great equal 18 year , 4 . Patients must ambulatory Karnofsky performance status great equal 70 % , 5 . Patients must life expectancy great equal 3 month , 6 . Patients must meet follow screen hematologic value : Hemoglobin great equal 10g /dL Absolute Neutrophil Count great equal 1.5 x 10^9/L Platelets great equal 100 x 109/L , 7 . Patients must meet follow screen value liver function : Serum bilirubin less equal 1.5 x upper limit normal ( ULN ) ALAT ASAT less equal 2.5 x ULN ( unless relate liver metastasis , case less equal 5 x ULN ) , 8 . Patients must serum creatinine less equal 1.5 x ULN , 9 . Patients must willing able comply study protocol duration study , 10 . Patients must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . 1 . Patients receive chemotherapy radiation therapy ( except palliative ) major surgery within four week treatment start , 2 . Patients receive chemotherapy without recover chemotherapy relate toxicity ( define grade 1 less ) study entry , 3 . Patients receive palliative radiation therapy without recover radiation associate toxicity study entry , 4 . Patients history hypersensitivity irinotecan , 5 . Patients experience great equal Grade 3 toxicity previous therapy irinotecan , 6 . Women pregnant breastfeeding . Women childbearing potential either positive pregnancy test screening pregnancy test . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) , 7 . Fertile men willing use contraception fertile men female partner willing use contraception , 8 . Any history uncontrolled seizure ; CNS disorder ; psychological , familial , sociological geographical condition , judge Investigator clinically significant , and/or potentially capable precluding inform consent adversely affect compliance study protocol followup schedule , 9 . Patients must untreated brain metastasis ( Patients treat CNS metastasis must asymptomatic radiologically stable 4 week prior entry ) , 10 . Patients history conjugate hyperbilirubinemia , 11 . Patients clinically significant cardiac cardiovascular impairment , 12 . Patients severe uncontrolled intercurrent infection , 13 . Patients organ allograft , 14 . Patients receive investigational drug treatment , immunotherapy , biologic therapy . Treatment must complete four week prior entry study patient must recover associated toxicity . 15 . Patients history hypersensitivity sulfonamide , 16 . Patients surgically resectable metastatic disease , 17 . Patients know positive hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) , Hepatitis C antibody , human immunodeficiency virus , 18 . Patients significant disease , Investigator 's opinion , would exclude patient study , 19 . Patients legally incapacitate , 20 . Patients repeat demonstration QTc great 470 m ( Bazett 's correction ) , 21 . Patients tumor , include metastasis , surgically resectable , 22 . Patients clinical symptom brain metastasis , 23 . Patients take steroids treatment brain metastasis , 24 . Patients leptomeningeal metastasis , 25 . Patients history additional risk factor torsades de pointes ( e.g. , heart failure ) family history Long QT Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>E7070</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>hydrochloride</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>cancer</keyword>
</DOC>